Vivimed Labs is currently trading at Rs 248.05, up by 1.65 points or 0.67% from its previous closing of Rs 246.40 on the BSE.
The scrip opened at Rs 252.00 and has touched a high and low of Rs 257.00 and Rs 246.00 respectively. So far 13190 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 330.00 on 02-Dec-2010 and a 52 week low of Rs 212.50 on 18-Nov-2011.
Last one week high and low of the scrip stood at Rs 257.00 and Rs 226.25 respectively. The current market cap of the company is Rs 343.33 crore.
The promoters holding in the company stood at 40.46% while Institutions and Non-Institutions held 19.74% and 39.80% respectively.
In a move to bring in strategic growth into its product mix and expand the footprint in Europe and the America, Vivimed Labs has acquired Uquifa Spain and Uquifa Mexico, a 75-year-old manufacturer of pharma APIs and intermediates with operations in Spain and Mexico.
This move would strengthen the company’s current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa. While Uquifa gets the supply side efficiencies and knowledge base of Vivimed in pharma, Vivimed would leverage the preeminent position of Uquifa in APIs and their robust pipeline of filings to accelerate growth across Europe and the Americas in the next five years.
The acquisition of Uquifa will add to Vivimed’s multi-geographical locations and knowledge base. This will fundamentally mean greater comfort levels for customers and channel partners. The Uquifa acquisition in Europe comes after 2008, post a successful acquisition and integration of James Robinson in UK.
Vivimed Labs is engaged in the business of manufacturing ingredients for the home and personal care (H&PC) industry and Contract Research and Manufacturing Services (CRAMS). It carries on its business from 4 manufacturing facilities which are located at Bidar (Karnataka), Jeedimetla (Hyderabad), Bonthapally (Hyderabad) and Kashipur (Uttaranchal).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: